<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00607893</url>
  </required_header>
  <id_info>
    <org_study_id>562</org_study_id>
    <secondary_id>K23HL079114</secondary_id>
    <nct_id>NCT00607893</nct_id>
  </id_info>
  <brief_title>Efficacy of Continuous Positive Airway Pressure in Reducing Oxidative Stress in Individuals With Sleep Apnea</brief_title>
  <acronym>SASS</acronym>
  <official_title>Oxidative Stress in Sleep Apnea and Cardiac Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Western Reserve University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleep-disordered breathing (SDB) is a condition in which a person experiences frequent
      breathing pauses during sleep, also known as sleep apnea. There is evidence that the
      recurrent sleep arousal and associated shortage of oxygen in the body may increase risk for
      cardiovascular disease (CVD). It is believed that treatment with continuous positive airway
      pressure (CPAP) may reduce certain risk factors for heart disease, including markers of
      inflammation and oxidative stress. This study will evaluate the effectiveness of CPAP in
      reducing CVD risk factors in people with SDB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is estimated that 18 million Americans are affected by SDB. SDB involves repeated sleep
      arousal caused by breathing difficulties. These frequent sleep disruptions may cause a person
      to experience daytime drowsiness, impaired mental functioning, and trouble concentrating or
      staying alert. SDB is also associated with an increased risk of certain cardiovascular
      diseases, such as high blood pressure and heart disease. Researchers believe that increased
      oxidative stress and inflammation associated with SDB may play a role in the physiologic
      pathway linking SDB and CVD. However, more information on the SDB-CVD relationship is needed
      to be able to identify risk factors for CVD and to discover the best means of treatment.
      CPAP, a current treatment for SDB, acts by delivering air through a mask during sleep. CPAP
      helps improve overnight breathing and quality of sleep and may, in turn, decrease oxidative
      stress and associated CVD risks. This study will compare the effectiveness of CPAP versus
      placebo CPAP in reducing CVD risk factors, such as oxidative stress markers, in people with
      SDB.

      Participation in this study will last between 2.5 and 4 months and will include four to five
      study visits. During the first study visit, participants will undergo a CPAP titration study,
      which will involve appropriate CPAP mask fitting and an overnight sleep test to determine the
      best CPAP pressure, as well as a lower placebo pressure, for each participant. Participants
      will also be provided educational information on diet, sleep, and the use of CPAP as a
      treatment for sleep apnea. After the titration study, participants will be asked to wear
      their fitted CPAP mask every night for the next 2 weeks, during which they will use the lower
      (placebo) pressure one week and use the higher pressure the other week. During this time, a
      technician will contact participants every 3 to 4 days to address any questions or problems
      with the CPAP equipment.

      One month later, participants who were able to tolerate and use CPAP most nights will attend
      Visit 2. This second visit will include an overnight sleep study without wearing the CPAP
      mask; blood and saliva collection; cheek brushing for genetic material; tests on diabetes,
      artery stiffness, and circulation; body fat measurements; and questionnaires. Participants
      will then be randomly assigned to use either the higher pressure CPAP or the lower pressure
      CPAP for 8 weeks. Visit 3 will occur 1 week after beginning CPAP treatment and will include a
      fasting blood test. During treatment, participants will be periodically contacted by a
      technician to check on equipment status.

      Upon completing treatment, participants will undergo repeat tests from Visit 2, except that
      they will wear the CPAP mask in the overnight sleep test. This fourth study visit will mark
      the completion of treatment for participants assigned to the lower pressure CPAP.
      Participants assigned to the higher pressure CPAP will be asked to use CPAP for 4 more weeks.
      These participants will return at the end of the 4 weeks for a final visit, which will
      include a repeat sleep study and other testing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>F2-isoprostanes/Cr</measure>
    <time_frame>Measured between baseline and after treatment</time_frame>
    <description>Oxidative stress outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myeloperoxidase</measure>
    <time_frame>Measured between baseline and after treatment</time_frame>
    <description>Oxidative stress outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Arterial BP, Evening</measure>
    <time_frame>Measured between baseline and after treatment</time_frame>
    <description>Blood pressure outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Wave Velocity, Evening</measure>
    <time_frame>Measured between baseline and after treatment</time_frame>
    <description>Pulse wave analysis outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>Measured between baseline and after treatment</time_frame>
    <description>Measures of inflammation outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Arterial BP, Morning</measure>
    <time_frame>Measured between baseline and after treatment</time_frame>
    <description>Blood pressure outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sIL-6R</measure>
    <time_frame>Measured between baseline and after treatment</time_frame>
    <description>Measures of inflammation outcome, logarithm transformed before analysis due to skewed distribution, analyzed change of from baseline with adjustment of baseline. The least squares mean is transformed back to present the percent change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Wave Velocity, Morning</measure>
    <time_frame>Measured between Months 2 and 3 of treatment</time_frame>
    <description>Pulse wave analysis outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index, Evening</measure>
    <time_frame>Measured between Months 2 and 3 of treatment</time_frame>
    <description>Pulse wave analysis outcome (a ratio of the augmentation of central aortic pressure by a reflected pulse wave, calculated from the blood pressure waveform), analyzed absolute change from baseline, with adjustment of baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index, Morning</measure>
    <time_frame>Measured between Months 2 and 3 of treatment</time_frame>
    <description>Pulse wave analysis outcome (a ratio of the augmentation of central aortic pressure by a reflected pulse wave, calculated from the blood pressure waveform), analyzed absolute change from baseline, with adjustment of baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Sleep Apnea Syndromes</condition>
  <condition>Oxidative Stress</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Sham CPAP</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants will receive sham continuous positive airway pressure (CPAP) for a 2 month period. Sham CPAP involves wearing a device that appears similar to a standard CPAP device, but administers a negligible pressure. Adherence will be tracked while the participant wears the device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment CPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive continuous positive airway pressure for a 2 month period. The optimal treatment pressure will be identified during a titration study prior to trial enrollment. Adherence will be tracked while the participant wears the device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Positive Airway Pressure (CPAP)</intervention_name>
    <description>Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.</description>
    <arm_group_label>Treatment CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham CPAP</intervention_name>
    <description>Participants will use the lower pressure CPAP every night for 8 weeks.</description>
    <arm_group_label>Sham CPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe sleep disordered breathing (SDB) (Apnea Hypopnea Index [AHI]
             greater than or equal to 15) diagnosed within the 2 months before study entry

          -  Able to participate in more than two overnight/daytime sleep and physiologic
             assessments over a 2.5-month period

        Exclusion Criteria:

          -  Current or planned use of specific sleep apnea treatments (e.g., CPAP, oral appliance)
             outside of the study

          -  Anticipated upper airway surgery or gastric bypass surgery in the 4 months after study
             completion

          -  Supplemental oxygen use

          -  Primary sleep disorder other than sleep apnea (e.g., periodic limb movement disorder)

          -  Severe chronic insomnia or circadian rhythm disorder with less than 4 hours of sleep
             per night, chronic problems falling asleep within 1 hour of bedtime, or chronic
             problems with early morning awakenings

          -  Unstable medical conditions (e.g., new onset or changing angina; heart attack or
             congestive heart failure exacerbation documented within the 6 months before study
             entry; high grade cardiac dysrhythmia/heart block; known unaddressed coronary artery
             disease by history, angina, stroke, or uncontrolled hypertension or diabetes mellitus;
             thyroid disorder; cirrhosis; a non-skin cancer diagnosed within the 2 years before
             study entry)

          -  Inadequately treated psychiatric disorders or compromised competence

          -  Daytime sleepiness with reports of sleepiness while driving or during other situations
             that would present a risk for the subject or public (e.g., operating heavy equipment)

          -  Alcohol abuse

          -  Pregnancy

          -  Use of oral corticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reena Mehra, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mehra R, Storfer-Isser A, Kirchner HL, Johnson N, Jenny N, Tracy RP, Redline S. Soluble interleukin 6 receptor: A novel marker of moderate to severe sleep-related breathing disorder. Arch Intern Med. 2006 Sep 18;166(16):1725-31.</citation>
    <PMID>16983050</PMID>
  </reference>
  <reference>
    <citation>Mehra R, Principe-Rodriguez K, Kirchner HL, Strohl KP. Sleep apnea in acute coronary syndrome: high prevalence but low impact on 6-month outcome. Sleep Med. 2006 Sep;7(6):521-8. Epub 2006 Aug 23.</citation>
    <PMID>16931151</PMID>
  </reference>
  <reference>
    <citation>Mehra R, Benjamin EJ, Shahar E, Gottlieb DJ, Nawabit R, Kirchner HL, Sahadevan J, Redline S; Sleep Heart Health Study. Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. Am J Respir Crit Care Med. 2006 Apr 15;173(8):910-6. Epub 2006 Jan 19.</citation>
    <PMID>16424443</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2008</study_first_submitted>
  <study_first_submitted_qc>January 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <results_first_submitted>April 6, 2017</results_first_submitted>
  <results_first_submitted_qc>August 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 15, 2017</results_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Case Western Reserve University</investigator_affiliation>
    <investigator_full_name>Reena Mehra</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Sleep-Disordered Breathing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sham CPAP</title>
          <description>Participants will receive sham continuous positive airway pressure for a 2 month period. Sham CPAP involves wearing a device that appears similar to a standard CPAP device, but administers a negligible pressure. Adherence will be tracked while the participant wears the device.
Sham treatment: Participants will use the lower pressure CPAP every night for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Treatment CPAP</title>
          <description>Participants will receive continuous positive airway pressure for a 2 month period. The optimal treatment pressure will be identified during a titration study prior to trial enrollment. Adherence will be tracked while the participant wears the device.
Continuous Positive Airway Pressure (CPAP): Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Baseline Visit</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 8 Week Visit</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 12 Week Visit</title>
              <participants_list>
                <participants group_id="P1" count="0">12 Week Visit only offered to participants on actual CPAP Treatment</participants>
                <participants group_id="P2" count="29">12 Week Visit only offered to participants on actual CPAP Treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>withdrew due to loss of interest</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew due to osteomyelitis surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>withdrew could not tolerate CPAP</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Declined to be treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew due to hypertensive urgency</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment CPAP</title>
          <description>Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Sham CPAP</title>
          <description>Participants used the Sham CPAP every night for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="149"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="11.7"/>
                    <measurement group_id="B2" value="51.7" spread="11.8"/>
                    <measurement group_id="B3" value="51.0" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>F2-isoprostanes/Cr</title>
        <description>Oxidative stress outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
        <time_frame>Measured between baseline and after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham CPAP</title>
            <description>Participants will use the lower pressure CPAP every night for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment CPAP</title>
            <description>Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>F2-isoprostanes/Cr</title>
          <description>Oxidative stress outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
          <units>ng/mg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.12" upper_limit="0.10"/>
                    <measurement group_id="O2" value="-0.08" lower_limit="-0.18" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.071</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.090</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
            <estimate_desc>F2-isoprostanes/Cr was log-transformed before analysis. The estimation parameter shows the log-transformed mean difference of the absolute change between groups, while the least square means of two groups are transformed back for presentation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Myeloperoxidase</title>
        <description>Oxidative stress outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
        <time_frame>Measured between baseline and after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham CPAP</title>
            <description>Participants will use the lower pressure CPAP every night for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment CPAP</title>
            <description>Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Myeloperoxidase</title>
          <description>Oxidative stress outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
          <units>pmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.33" lower_limit="-17.02" upper_limit="10.37"/>
                    <measurement group_id="O2" value="-5.15" lower_limit="-18.65" upper_limit="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.42</ci_lower_limit>
            <ci_upper_limit>21.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Arterial BP, Evening</title>
        <description>Blood pressure outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
        <time_frame>Measured between baseline and after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham CPAP</title>
            <description>Participants will use the lower pressure CPAP every night for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment CPAP</title>
            <description>Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Arterial BP, Evening</title>
          <description>Blood pressure outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" lower_limit="-2.53" upper_limit="1.35"/>
                    <measurement group_id="O2" value="-0.72" lower_limit="-2.65" upper_limit="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.60</ci_lower_limit>
            <ci_upper_limit>2.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Wave Velocity, Evening</title>
        <description>Pulse wave analysis outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
        <time_frame>Measured between baseline and after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham CPAP</title>
            <description>Participants will use the lower pressure CPAP every night for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment CPAP</title>
            <description>Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Wave Velocity, Evening</title>
          <description>Pulse wave analysis outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
          <units>cm/s</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" lower_limit="-0.57" upper_limit="0.40"/>
                    <measurement group_id="O2" value="-0.30" lower_limit="-0.80" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-6</title>
        <description>Measures of inflammation outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
        <time_frame>Measured between baseline and after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham CPAP</title>
            <description>Participants will use the lower pressure CPAP every night for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment CPAP</title>
            <description>Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>IL-6</title>
          <description>Measures of inflammation outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" lower_limit="-0.10" upper_limit="0.68"/>
                    <measurement group_id="O2" value="-0.08" lower_limit="-0.46" upper_limit="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Arterial BP, Morning</title>
        <description>Blood pressure outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
        <time_frame>Measured between baseline and after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham CPAP</title>
            <description>Participants will use the lower pressure CPAP every night for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment CPAP</title>
            <description>Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Arterial BP, Morning</title>
          <description>Blood pressure outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="-1.64" upper_limit="2.12"/>
                    <measurement group_id="O2" value="-2.17" lower_limit="-4.03" upper_limit="-0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.076</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>5.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>sIL-6R</title>
        <description>Measures of inflammation outcome, logarithm transformed before analysis due to skewed distribution, analyzed change of from baseline with adjustment of baseline. The least squares mean is transformed back to present the percent change from baseline.</description>
        <time_frame>Measured between baseline and after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham CPAP</title>
            <description>Participants will use the lower pressure CPAP every night for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment CPAP</title>
            <description>Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>sIL-6R</title>
          <description>Measures of inflammation outcome, logarithm transformed before analysis due to skewed distribution, analyzed change of from baseline with adjustment of baseline. The least squares mean is transformed back to present the percent change from baseline.</description>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="-0.02" upper_limit="0.06"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-0.08" upper_limit="-0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.062</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.010</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
            <estimate_desc>sIL-6R was log-transformed before analysis. The estimation parameter shows the log-transformed mean difference of the absolute change between groups, while the least square means of two groups are transformed back for presentation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Wave Velocity, Morning</title>
        <description>Pulse wave analysis outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
        <time_frame>Measured between Months 2 and 3 of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham CPAP</title>
            <description>Participants will use the lower pressure CPAP every night for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment CPAP</title>
            <description>Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Wave Velocity, Morning</title>
          <description>Pulse wave analysis outcome, analyzed absolute change from baseline, with adjustment of baseline</description>
          <units>cm/s</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" lower_limit="-0.82" upper_limit="0.32"/>
                    <measurement group_id="O2" value="-0.42" lower_limit="-1.01" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Augmentation Index, Evening</title>
        <description>Pulse wave analysis outcome (a ratio of the augmentation of central aortic pressure by a reflected pulse wave, calculated from the blood pressure waveform), analyzed absolute change from baseline, with adjustment of baseline</description>
        <time_frame>Measured between Months 2 and 3 of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham CPAP</title>
            <description>Participants will use the lower pressure CPAP every night for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment CPAP</title>
            <description>Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Augmentation Index, Evening</title>
          <description>Pulse wave analysis outcome (a ratio of the augmentation of central aortic pressure by a reflected pulse wave, calculated from the blood pressure waveform), analyzed absolute change from baseline, with adjustment of baseline</description>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" lower_limit="-3.87" upper_limit="3.00"/>
                    <measurement group_id="O2" value="-1.79" lower_limit="-5.36" upper_limit="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.60</ci_lower_limit>
            <ci_upper_limit>6.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Augmentation Index, Morning</title>
        <description>Pulse wave analysis outcome (a ratio of the augmentation of central aortic pressure by a reflected pulse wave, calculated from the blood pressure waveform), analyzed absolute change from baseline, with adjustment of baseline</description>
        <time_frame>Measured between Months 2 and 3 of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham CPAP</title>
            <description>Participants will use the lower pressure CPAP every night for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment CPAP</title>
            <description>Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Augmentation Index, Morning</title>
          <description>Pulse wave analysis outcome (a ratio of the augmentation of central aortic pressure by a reflected pulse wave, calculated from the blood pressure waveform), analyzed absolute change from baseline, with adjustment of baseline</description>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" lower_limit="-2.22" upper_limit="3.10"/>
                    <measurement group_id="O2" value="-6.49" lower_limit="-9.32" upper_limit="-3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.04</ci_lower_limit>
            <ci_upper_limit>10.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SHAM CPAP</title>
          <description>Participants will receive sham continuous positive airway pressure for a 2 month period. Sham CPAP involves wearing a device that appears similar to a standard CPAP device, but administers a negligible pressure. Adherence will be tracked while the participant wears the device.
Sham CPAP: Participants will use the lower pressure CPAP every night for 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Treatment CPAP</title>
          <description>Participants will receive continuous positive airway pressure for a 2 month period. The optimal treatment pressure will be identified during a titration study prior to trial enrollment. Adherence will be tracked while the participant wears the device.
Continuous Positive Airway Pressure (CPAP): Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Run-in/Washout Treatment CPAP</title>
          <description>The initial run-in and washout period for study qualification to document CPAP adherence on treatment CPAP.</description>
        </group>
        <group group_id="E4">
          <title>Run-in/Washout Sham CPAP</title>
          <description>The initial run-in and washout period for study qualification to document CPAP adherence on Sham CPAP (negligible pressure).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain (went to ER)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Enlarged coronary artieries/chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Irregular heartbeat (went to ER)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>New onset atrial flutter (shown on psg)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ER with swollen Knee (hospitalized)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration and possible kidney failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pneumonia/Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Spot on lung - biopsy for cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Foot ulcer amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Ruptured appendix</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bruise from venipucture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Nose bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Elevated blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Heart monitor for irregular heartbeat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Run of nonsustained ventricular tachycardia on PSG</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Eye infection/injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal cramping</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated glucose level</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="77"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Developed sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Fell and bruised rib</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>General pain (leg, back, muscle)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hand injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Knee replacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>auto accident / physical therapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Breathing problems</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cold/congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dry cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Non-productive cough/post nasal drip</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Spot on lung (possible cancer)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Strep throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abrasion on bridge of nose from CPAP mask</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cysts on chin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Flare up of eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Redness on external nares from nasal pillow mask marks on face from maks</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Tumor removed from finger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Ulcer on foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>scabs on head from electrodes from psg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Kidney Stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Tooth extracted/root canal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Reena Mehra</name_or_title>
      <organization>Case Western Reserve University</organization>
      <phone>216-445-1698</phone>
      <email>mehrar@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

